6-ethyl-3-methyl-4-phenylisoxazolo[3,4-d]pyridazin-7(6H)-one | 189306-91-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-ethyl-3-methyl-4-phenylisoxazolo[3,4-d]pyridazin-7(6H)-one
• 英文别名: 6-ethyl-3-methyl-4-phenyl-[1,2]oxazolo[3,4-d]pyridazin-7-one
• CAS: 189306-91-0
• 化学式: C₁₄H₁₃N₃O₂
• 分子量: 255.276
• InChiKey: ZRBZYDHSBWCOQZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  58.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-ethyl-3-methyl-4-phenylisoxazolo[3,4-d]pyridazin-7(6H)-one 在 钯 氢气 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以to yield the title compound (1.97 g, 98% yield)的产率得到5-acetyl-4-amino-2-ethyl-6-phenylpyridazin-3(2H)-one
  参考文献：
  名称：

  Pyridazin-3(2H)-one derivatives as PDE4 inhibitors

  摘要：

  本发明揭示了具有通式（I）的化学结构的新吡啶并嗪-3（2H）-酮衍生物，以及它们的制备方法，包括它们的药物组成物和它们作为磷酸二酯酶4抑制剂在治疗中的使用。

  公开号：

  US07459453B2
• 作为产物：
  描述：

  溴乙烷 、 3-甲基-4-苯基异恶唑并[3,4-d]哒嗪-7(6H)-酮 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 以59%的产率得到6-ethyl-3-methyl-4-phenylisoxazolo[3,4-d]pyridazin-7(6H)-one
  参考文献：
  名称：

  Novel Heterocyclic-Fused Pyridazinones as Potent and Selective Phosphodiesterase IV Inhibitors

  摘要：

  A series of 6-aryl-4,5-heterocyclic-fused pyridazinones were designed and synthesized as selective phosphodiesterase (PDE) TV inhibitors. Biological evaluation of these compounds demonstrated a good selectivity profile toward the PDE TV family and greatly attenuated affinity for the Rolipram high-affinity binding site that seems to be responsible for undesiderable side effects. Structure-activity relationships (SARs) studies showed that the presence of an ethyl group at pyridazine N-2 is associated with the best potency and selectivity profile.

  DOI：

  10.1021/jm970105l

文献信息

• [EN] PYRIDAZIN-3 (2H) -ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS<br/>[FR] DERIVES DE PYRIDAZINE-3(2H)-ONES ET UTILISATION EN TANT QU'INHIBITEURS DE PDE4
  申请人：ALMIRALL PRODESFARMA SA

  公开号：WO2005049581A1

  公开（公告）日：2005-06-02

  New pyridazin-e-(2H)-one derivatives having the chemical structure of general formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of phosphodiesterase 4.

  新吡啶唑-e-(2H)-酮衍生物，具有通用公式(I)的化学结构被公开；以及它们的制备过程，包含它们的药物组合物以及它们作为磷酸二酯酶4抑制剂的疗法使用。
• [EN] NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES<br/>[FR] NOUVEAUX DERIVES DE PYRIDAZIN-3(2H)-ONE
  申请人：ALMIRALL PRODESFARMA SA

  公开号：WO2004058729A1

  公开（公告）日：2004-07-15

  Pyridazin-3(2H)-one derivatives of formula (I) are found to inhibit PDE-4:, wherein R1, R2 and R4 are organic radicals, R3 is a cyclic group, and R5 is an ester or an aryl or heteroaryl group.

  式(I)的吡啶嗪-3(2H)-酮衍生物被发现能抑制PDE-4：其中R1、R2和R4为有机基团，R3为环状基团，R5为酯基或芳基或杂芳基。
• [EN] PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS<br/>[FR] DERIVES DE LA PYRIDAZINE-3(2h)-ONE, INHIBITEURS DE LA PDE4
  申请人：ALMIRALL PRODESFARMA SA

  公开号：WO2003097613A1

  公开（公告）日：2003-11-27

  New pyridazin-3(2H)-one derivatives having the chemical structure of general formula (I); are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of phosphodiesterase 4.

  新的吡啶并嗪-3(2H)-酮衍生物具有一般式(I)的化学结构；公开了它们的制备方法，包括它们的药物组合物以及它们作为磷酸二酯酶4抑制剂在治疗中的用途。
• New pyridazin-3(2h)-one derivatives
  申请人：Dal Piaz Vittorio

  公开号：US20060173008A1

  公开（公告）日：2006-08-03

  Pyridazin-3(2H)-one derivatives of formula (I) are found to inhibit PDE-4. R 1 , R 2 and R 4 are organic radicals, R 3 is a cyclic group, and R 5 is an ester or an aryl or heteroaryl group.

  公式（I）的吡啶并嗪-3（2H）-酮衍生物被发现可以抑制PDE-4。R1，R2和R4是有机基团，R3是一个环状基团，R5是酯基或芳基或杂环基团。
• Pyridazin-3(2h)-one derivatives as pde4 inhibitors
  申请人：Dal Piaz Vittorio

  公开号：US20060052379A1

  公开（公告）日：2006-03-09

  New pyridazin-3(2H)-one derivatives having the chemical structure of general formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of phosphodiesterase 4.

  本发明公开了具有一般式(I)化学结构的新吡啶并嗪-3(2H)-酮衍生物；以及其制备过程、包含它们的制药组合物以及它们作为磷酸二酯酶4抑制剂在治疗中的应用。